Literature DB >> 25168239

Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking.

B Martin-Antonio1, A Najjar2, S N Robinson3, C Chew3, S Li3, E Yvon3, M W Thomas3, I Mc Niece3, R Orlowski4, C Muñoz-Pinedo5, C Bueno6, P Menendez7, C Fernández de Larrea8, A Urbano-Ispizua8, E J Shpall3, N Shah3.   

Abstract

Natural killer cells (NK) are important effectors of anti-tumor immunity, activated either by the downregulation of HLA-I molecules on tumor cells and/or the interaction of NK-activating receptors with ligands that are overexpressed on target cells upon tumor transformation (including NKG2D and NKP30). NK kill target cells by the vesicular delivery of cytolytic molecules such as Granzyme-B and Granulysin activating different cell death pathways, which can be Caspase-3 dependent or Caspase-3 independent. Multiple myeloma (MM) remains an incurable neoplastic plasma-cell disorder. However, we previously reported the encouraging observation that cord blood-derived NK (CB-NK), a new source of NK, showed anti-tumor activity in an in vivo murine model of MM and confirmed a correlation between high levels of NKG2D expression by MM cells and increased efficacy of CB-NK in reducing tumor burden. We aimed to characterize the mechanism of CB-NK-mediated cytotoxicity against MM cells. We show a Caspase-3- and Granzyme-B-independent cell death, and we reveal a mechanism of transmissible cell death between cells, which involves lipid-protein vesicle transfer from CB-NK to MM cells. These vesicles are secondarily transferred from recipient MM cells to neighboring MM cells amplifying the initial CB-NK cytotoxicity achieved. This indirect cytotoxicity involves the transfer of NKG2D and NKP30 and leads to lysosomal cell death and decreased levels of reactive oxygen species in MM cells. These findings suggest a novel and unique mechanism of CB-NK cytotoxicity against MM cells and highlight the importance of lipids and lipid transfer in this process. Further, these data provide a rationale for the development of CB-NK-based cellular therapies in the treatment of MM.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25168239      PMCID: PMC4262774          DOI: 10.1038/cdd.2014.120

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  37 in total

Review 1.  A quarter century of granzymes.

Authors:  C L Ewen; K P Kane; R C Bleackley
Journal:  Cell Death Differ       Date:  2011-11-04       Impact factor: 15.828

2.  Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.

Authors:  Brenna E Swift; Brent A Williams; Yoko Kosaka; Xing-Hua Wang; Jeffrey A Medin; Sowmya Viswanathan; Joaquin Martinez-Lopez; Armand Keating
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

Review 3.  Lysosomal cell death at a glance.

Authors:  Sonja Aits; Marja Jäättelä
Journal:  J Cell Sci       Date:  2013-05-01       Impact factor: 5.285

Review 4.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

5.  Control of autophagic cell death by caspase-10 in multiple myeloma.

Authors:  Laurence Lamy; Vu N Ngo; N C Tolga Emre; Arthur L Shaffer; Yandan Yang; Erming Tian; Vinod Nair; Michael J Kruhlak; Adriana Zingone; Ola Landgren; Louis M Staudt
Journal:  Cancer Cell       Date:  2013-03-28       Impact factor: 31.743

Review 6.  Role of cholesterol and lipid organization in disease.

Authors:  Frederick R Maxfield; Ira Tabas
Journal:  Nature       Date:  2005-12-01       Impact factor: 49.962

7.  Granulysin induces cathepsin B release from lysosomes of target tumor cells to attack mitochondria through processing of bid leading to Necroptosis.

Authors:  Honglian Zhang; Chao Zhong; Lei Shi; Yuming Guo; Zusen Fan
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

8.  Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.

Authors:  Pieter Sonneveld; Hartmut Goldschmidt; Laura Rosiñol; Joan Bladé; Juan José Lahuerta; Michele Cavo; Paola Tacchetti; Elena Zamagni; Michel Attal; Henk M Lokhorst; Avinash Desai; Andrew Cakana; Kevin Liu; Helgi van de Velde; Dixie-Lee Esseltine; Philippe Moreau
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

Review 9.  Endocytosis as a mechanism of regulating natural killer cell function: unique endocytic and trafficking pathway for CD94/NKG2A.

Authors:  Giovanna Peruzzi; Madhan Masilamani; Francisco Borrego; John E Coligan
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

Review 10.  DangER: protein ovERload. Targeting protein degradation to treat myeloma.

Authors:  Lauren I Aronson; Faith E Davies
Journal:  Haematologica       Date:  2012-05-11       Impact factor: 9.941

View more
  10 in total

1.  Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.

Authors:  Nina Shah; Li Li; Jessica McCarty; Indreshpal Kaur; Eric Yvon; Hila Shaim; Muharrem Muftuoglu; Enli Liu; Robert Z Orlowski; Laurence Cooper; Dean Lee; Simrit Parmar; Kai Cao; Catherine Sobieiski; Rima Saliba; Chitra Hosing; Sairah Ahmed; Yago Nieto; Qaiser Bashir; Krina Patel; Catherine Bollard; Muzaffar Qazilbash; Richard Champlin; Katy Rezvani; Elizabeth J Shpall
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

Review 2.  Tumor Secretome to Adoptive Cellular Immunotherapy: Reduce Me Before I Make You My Partner.

Authors:  Mikel Etxebeste-Mitxeltorena; Inés Del Rincón-Loza; Beatriz Martín-Antonio
Journal:  Front Immunol       Date:  2021-08-10       Impact factor: 7.561

Review 3.  Targeted Therapies in Adult B-Cell Malignancies.

Authors:  Jean-François Rossi
Journal:  Biomed Res Int       Date:  2015-09-06       Impact factor: 3.411

Review 4.  Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.

Authors:  Gianfranco Pittari; Luca Vago; Moreno Festuccia; Chiara Bonini; Deena Mudawi; Luisa Giaccone; Benedetto Bruno
Journal:  Front Immunol       Date:  2017-11-07       Impact factor: 7.561

5.  Extracellular NK histones promote immune cell anti-tumor activity by inducing cell clusters through binding to CD138 receptor.

Authors:  B Martín-Antonio; G Suñe; A Najjar; L Perez-Amill; A Antoñana-Vildosola; M Castella; S León; M Velasco-de Andrés; F Lozano; E Lozano; C Bueno; J M Estanyol; C Muñoz-Pinedo; S N Robinson; A Urbano-Ispizua
Journal:  J Immunother Cancer       Date:  2019-10-16       Impact factor: 13.751

6.  Systemic β-Adrenergic Receptor Activation Augments the ex vivo Expansion and Anti-Tumor Activity of Vγ9Vδ2 T-Cells.

Authors:  Forrest L Baker; Austin B Bigley; Nadia H Agha; Charles R Pedlar; Daniel P O'Connor; Richard A Bond; Catherine M Bollard; Emmanuel Katsanis; Richard J Simpson
Journal:  Front Immunol       Date:  2020-01-24       Impact factor: 7.561

Review 7.  Inflammaging, an Imbalanced Immune Response That Needs to Be Restored for Cancer Prevention and Treatment in the Elderly.

Authors:  Juana Serrano-López; Beatriz Martín-Antonio
Journal:  Cells       Date:  2021-09-28       Impact factor: 6.600

Review 8.  A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments.

Authors:  Rosario Hervás-Salcedo; Beatriz Martín-Antonio
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

Review 9.  Natural Killer Cells: Angels and Devils for Immunotherapy.

Authors:  Beatriz Martín-Antonio; Guillermo Suñe; Lorena Perez-Amill; Maria Castella; Alvaro Urbano-Ispizua
Journal:  Int J Mol Sci       Date:  2017-08-29       Impact factor: 5.923

Review 10.  Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer.

Authors:  Xiaoyan Zhao; Li Cai; Yu Hu; Huafang Wang
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.